Soluble trail as a marker of efficacy of allergen-specific immunotherapy in patients with allergic rhinoconjunctivitis

Yalçın, Arzu Didem; Gümüşlü, Saadet; Parlak, Gizem Esra; Bişgin, Atıl

doi:10.12659/msm.883488

Cited by 10 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our earlier studies provided a novel perspective on allergic asthma and the effect of anti IgE treatment, using as markers serum soluble TNF-related apoptosis-inducing ligand, total antioxidant capacity, hydrogen peroxide, malondialdehyde total nitric oxide concentrations and ceruloplasmin oxidase activity measurements [29][30][31][32]. Taken together, our results and those of others suggest that characterization of the specific receptor systems activated, and the pro-inflammatory factors regulated, by TRAIL in vivo may lead to the development of novel therapeutic strategies for diseases as diverse as allergy [29,33]. The sTRAIL levels were decreased after allergen-spesific immunotherapy as to healthy individuals' levels.…”

Section: Discussionsupporting

confidence: 61%

“…The sTRAIL levels were decreased after allergen-spesific immunotherapy as to healthy individuals' levels. be a marker of efficacy of immunotherapy in allergic rhinoconjunctivitis patients [33,34]. When allergic rhinitis diagnosis is made; a detailed history, physical examination with determination of the factors that trigger allergic rhinitis and measures to avoid the contact to the allergens must be performed.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Incidence of the Epidemiological Markers of Allergy in Adults

Yalçın¹

2014

Ann Clin Anal Med

View full text Add to dashboard Cite

were recorded. Results: Total Ig E level was 307.6 ± 14.5 kU/L. Age of 25.6 % of the patients was between 30-39 years. The most common irritant that exacerbates the allergic rhinitis and asthma symptoms was air pollution (%77.0) and house dust ranks second (%76.2). The SPT of the cases were evaluated taking the age groups into account and this revealed an decreased rate of positivity to the prick test for plants and cereals with increasing age (p<0.001). Among smokers grass, mold ,epidermal prick positivity was significant. Discussion: In allergic diseases; allergens may have regional variations.That's why; the allergen profiles of the regions must be determined and the dermal Prick tests must be prepared accordingly.

show abstract

Section: Discussionsupporting

confidence: 61%

Section: Discussionmentioning

confidence: 99%

The Incidence of the Epidemiological Markers of Allergy in Adults

Yalçın¹

2014

Ann Clin Anal Med

View full text Add to dashboard Cite

show abstract

“…Furthermore, no clear relationship between serum cytokines and clinical outcome of AIT has been demonstrated. Besides addressing interleukins, numerous studies during AIT investigated chemokines CCR3 (unchanged) and CCR4 (increased) and other original serum markers, like adiponectin (unchanged), apolipoprotein A‐IV (increased), beta thromboglobulin (unchanged), complement factors C3a and 5a (decreased), C4a (increased), ECP (unchanged), eotaxin (increased/decreased), soluble HLA molecules (unchanged), leptin (unchanged or increased), signalling lymphocytic activation molecule (increased), thymus and activation‐regulated chemokine (TARC) (increased), TRAIL (reduced), transthyretin (increased) to tryptase (unchanged). Importantly, none of these markers showed any correlation with the clinical response.…”

Section: Resultsmentioning

confidence: 99%

Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper

Shamji

Kappen

Akdiş

et al. 2017

Allergy

306

367

View full text Add to dashboard Cite

Background: Allergen immunotherapy (AIT) is an effective treatment for allergic rhinoconjunctivitis (AR) with or without asthma. It is important to note that due to the complex interaction between patient, allergy triggers, symptomatology and vaccines used for AIT, some patients do not respond optimally to the treatment. Furthermore, there are no validated or generally accepted candidate biomarkers that are predictive of the clinical response to AIT. Clinical management of patients receiving AIT and efficacy in randomised controlled trials for drug development could be enhanced by predictive biomarkers. Method: The EAACI taskforce reviewed all candidate biomarkers used in clinical trials of AR patients with/without asthma in a literature review. Biomarkers were grouped into seven domains: (i) IgE (total IgE, specific IgE and sIgE/Total IgE ratio), (ii) IgG-subclasses (sIgG1, sIgG4 including SIgE/IgG4 ratio), (iii) Serum inhibitory activity for IgE (IgE-FAB and IgE-BF), (iv) Basophil activation, (v) Cytokines and Chemokines, (vi) Cellular markers (T regulatory cells, B regulatory cells and dendritic cells) and (vii) In vivo biomarkers (including provocation tests?). Results: All biomarkers were reviewed in the light of their potential advantages as well as their respective drawbacks. Unmet needs and specific recommendations on all seven domains were addressed.

show abstract

“…It has been proven that circulating TRAIL and DR5 play important roles in many diseases, such as cancer, 29 – 31 asthma, 32 allergic rhinoconjunctivitis, 33 scleroderma, 34 and chronic hepatitis B. 35 Recent studies have also connected TRAIL and its receptors to COPD.…”

Section: Discussionmentioning

confidence: 99%

Increased serum TRAIL and DR5 levels correlated with lung function and inflammation in stable COPD patients

Wu¹,

Shen²,

Zhang³

et al. 2015

COPD

View full text Add to dashboard Cite

BackgroundChronic obstructive pulmonary disease (COPD) is associated with abnormal systemic inflammation, and apoptosis is one of the pathogenic mechanisms of COPD. Several studies have suggested that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors were not only involved in diseases associated with apoptosis but also in inflammatory diseases. However, limited data about the possible relationship between COPD and TRAIL/TRAIL-receptors are available.ObjectiveTo evaluate the potential relationship between TRAIL/TRAIL-receptors and COPD.MethodsSerum levels of TRAIL, decoy receptor 5 (DR5), C-reactive protein, and tumor necrosis factor-α were analyzed using multiplex enzyme-linked immunosorbent assay kits. Then, serum levels of TRAIL and DR5 in 57 COPD patients with 35 healthy controls were compared and correlated with lung function and systemic inflammation.ResultsMean levels of serum TRAIL and DR5 were significantly higher in COPD patients than those in controls (50.17±17.70 versus 42.09±15.49 pg/mL, P=0.029; 48.15±22.88 versus 38.94±10.95 pg/mL, P=0.032, respectively). Serum levels of TRAIL and DR5 correlated inversely with forced expiratory volume in 1 second % predicted, an index of lung function in COPD (r=-0.354, P=0.007 for TRAIL; r=−0.394, P=0.002 for DR5) in all participants (r=-0.291, P=0.005 for TRAIL; r=−0.315, P=0.002 for DR5), while DR5 correlated positively with C-reactive protein (r=0.240, P=0.021 for total subjects) and TRAIL correlated positively with tumor necrosis factor-α (r=0.371, P=0.005 for COPD; r=0.349, P=0.001 for total subjects).ConclusionOur results suggested that circulating TRAIL and DR5 increased in COPD patients and were associated with lung function and systemic inflammation in COPD. Future studies are needed to verify whether and how TRAIL and its receptors play roles in COPD.

show abstract

Soluble trail as a marker of efficacy of allergen-specific immunotherapy in patients with allergic rhinoconjunctivitis

Cited by 10 publications

References 23 publications

The Incidence of the Epidemiological Markers of Allergy in Adults

The Incidence of the Epidemiological Markers of Allergy in Adults

Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper

Increased serum TRAIL and DR5 levels correlated with lung function and inflammation in stable COPD patients

Contact Info

Product

Resources

About